What is ThinkCyte?
Founded in 2016, ThinkCyte is at the forefront of developing groundbreaking life science research, diagnostics, and treatments. The company leverages an integrated multidisciplinary approach, combining advanced hardware, machine learning, and biotechnology to offer a transformational single-cell technology. ThinkCyte's mission is to empower scientists and biomedical professionals by accelerating biological discoveries and enabling the creation of novel therapeutic and diagnostic solutions. The company's focus on innovation positions it as a key player in the rapidly evolving biotechnology landscape.
How much funding has ThinkCyte raised?
ThinkCyte has raised a total of $97.3M across 4 funding rounds:
Series A
$15.3M
Series B
$26M
Private Equity
$24M
Series C
$32M
Series A (2020): $15.3M with participation from Fuyo General Lease, SBI Group, SPARX Group, and Itochu Technology Ventures, Inc
Series B (2021): $26M led by SBI Group, ITOCHU Technology Ventures, Sysmex, Mirai Creation Fund/SPARX Asset Management, and Sumitomo Mitsui Trust Investment Co.
Private Equity (2023): $24M supported by Tokyo Century Corporation, Sumitomo Mitsui Trust Bank, and Nomura Holdings
Series C (2024): $32M featuring SMBC Venture Capital
Key Investors in ThinkCyte
Tokyo Century Corporation
Tokyo Century Corporation is a specialized financial services company that integrates finance, services, and business expertise to support customer growth. Its core businesses include equipment leasing, mobility and fleet management, specialty financing, and international business, aiming to enhance corporate value.
Sumitomo Mitsui Trust Bank
Sumitomo Mitsui Trust Bank, Limited, established in 1925, operates in trust banking, leasing, and finance primarily in Japan. It is a key entity within Sumitomo Mitsui Trust Holdings, offering a wide range of financial services.
Nomura Holdings
Nomura Holdings is a global financial services group with a strong presence in Asia. It provides retail, asset management, and wholesale services, including global markets and investment banking, to individuals, institutions, corporations, and governments.
What's next for ThinkCyte?
With the recent major strategic investment and a substantial total funding amount of $97.3M, ThinkCyte is poised for significant expansion. This capital injection, particularly the $32M received in its latest round, will likely fuel further research and development, enhance its technological capabilities, and potentially support market penetration efforts. The company's trajectory suggests a move towards scaling its operations and solidifying its position as a leader in single-cell analysis and its applications in medicine.
See full ThinkCyte company page
